Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Clinical trials handbook [[electronic resource] ] : design and conduct / / Curtis L. Meinert
| Clinical trials handbook [[electronic resource] ] : design and conduct / / Curtis L. Meinert |
| Autore | Meinert Curtis L |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Somerset, N.J., : Wiley, 2012 |
| Descrizione fisica | 1 online resource (599 p.) |
| Disciplina | 615.1072/4 |
| Soggetto topico |
Drugs - Testing
Clinical trials |
| ISBN |
1-118-42279-1
1-118-42287-2 1-118-42282-1 |
| Classificazione | REF028000 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: Preface xiOn planning xiiiExplanatory notes, focus, and conventions xvI. General 31. Terminology 42. Definitions 63. Measurement units 84. Trial type 95. Design and flow schematics 126. Design and operating principles 137. Counting and analysis rules 148. Multi-study umbrella name 169. Study name 18II. Design specifications 2110. Objective 2211. Specific aims 2412. Experimental variable 2513. Treatment unit 2614. Primary outcome 2815. Outcome measures 3116. Design synopsis 33III. Funding 3717. Type of funding initiative 3818. Funding: Specifications 4019. Funding: Terminology 4220. Funding: Type 5021. Funding: Initiative 5122. Funding: Period 5323. Funding: Budget 5424. Funding: Mode 56IV. Treatment groups/treatment administration 5925. Study groups 6026. Comparison group 6227. Study treatments 6428. Test treatments 6629. Control/comparison treatment 6830. Placebo treatment 7531. Sham treatment 8032. Treatment modality 8233. Treatment schedule 8334. Treatment compliance measures 8535. Protocol overrides 8836. Protocol bailouts 90V. Masking 9337. Mask/masking: Definitions 9438. Masking principles 9739. Masking, censoring, and shielding specifications 9940. Drug masking procedure 10141. Drug packaging and labeling 10342. Drug supply 10643. Masking safeguards 10844. Unmasking treatment assignment 10945. Results blackouts 110VI. Bias and variance control 11346. Bias control procedures 11447. Stratification 11748. Variance control procedures 12049. Separations 122VII. Treatment assignment/randomization 12350. Assignment methods: Fixed vs adaptive 12451. Treatment assignment: Random vs nonrandom 12652. Randomization: Complete vs restricted 12953. Randomization unit 13254. Randomization: Procedures 134VIII. IRBs and consents 13555. IRBs 13656. IRBs: Models and procedures 13857. Consent 14358. Consent: Checklist 15059. Consent: Disclaimers and notifications 15360. Consent: Principles and purpose 15561. Consent: Process 15762. Consent: Types 16063. Consent: Questions and answers 162IX. Enrollment and followup 16764. Notation 16865. Timing conventions 17166. Required approvals, permissions, accesses, and supplies 17367. Start-up design 17568. Start-up checklist 17969. Recruitment design 18070. Enrollment goals 18271. Enrollment quotas 18472. Followup: Terminology 18973. Followup: Method 19374. Followup: Length 19575. Closeout design 19676. Missed visit 19977. Dropout 20078. Loss to followup 20479. Study timetable 20780. Critical event path analysis 20981. Eligibility criteria 21282. Exclusions from enrollment 21583. Eligibility and exclusions by reason 219X. Sample size 22184. Sample size: Design 22285. Sample size: Specifications 22686. Sample size: Calculation 22987. Fixed versus sequential sample size designs 23188. Fixed versus adaptive designs 23389. Designed subgroup comparisons 235XI. Data collection and processing 23990. Contact schedule 24091. Examinations/visits 24192. Examination/clinic visit schedule 24593. Data collection 24994. Data collection: Schedules and procedures 25295. Data flow 25596. Data processing procedures 25797. Laboratory tests 26098. Readings 26299. Tissue repositories 266100. Form design: Principles and procedures 268101. Time window specifications 272102. Data entry design 274103. Data sharing: Internal 280104. Data sharing: External 283XII. Study centers 287105. Center types 288106. Centers 291107. Center requirements 293XIII. Investigators/study staff 297108. Investigator requirements 298109. Clinic staffing requirements 300110. Research group/Investigators 302XIV. Committees 305111. Key committees 306112. Standing and working committees 307113. Committee rules and procedures 308114. Study officers 312115. Study chair/vice-chair 313116. Executive committee 317117. Executive committee members 319118. Steering committee 320119. Steering committee members 322120. Steering committee: Questions, answers, and observations 324121. Steering committee representation models 327XV. Treatment effects monitoring 331122. Treatment effects monitoring 332123. Treatment effects monitoring: Purpose 334124. Treatment effects monitoring: Approach 336125. Treatment effects monitoring: Masking 338126. Stopping rules and guidelines 340127. Treatment effects monitoring: Questions and answers 342128. Treatment effects monitoring committee 345129. Treatment effects monitoring committee: Questions and answers 347XVI. Quality control and assurance 351130. Quality control and assurance procedures 352131. Performance monitoring 356132. Training procedures 358133. Assurances and certifications 359134. Site visiting procedures 361135. Audit procedures 364XVII. Data analysis 367136. Analysis datasets 368137. Analysis questions regarding study results publications 370138. Frequentist vs Bayesian analysis 372139. Final analysis 374140. Subgroup analysis 376XVIII. Publication/presentation 379141. Publication 380142. Publication policy 382143. Authorship 384144. Credits 389145. Presentation policy 393XIX. Policies 395146. Policies 396147. Publicity policy 397148. Policy on access to study documents 398149. Policy on access to study data and results 400150. Policy on advertising for patients 403151. Policy on incentive payments 404152. Policy on payment of patient related travel expenses 406153. Ancillary study policy 407154. Policy on patient care related payments 409155. Policy on conflicts of interest 410156. Substudy policy 413XX. Adverse events 415157. Adverse events 416158. Adverse event reporting procedures 420XXI. Miscellaneous 423159. Key study documents 424160. Design synopsis 425161. Slide sets 426162. Study CV 427163. Study website 428164. Study history log 429165. Landmark events and dates 431166. Registration 433Appendices 435Appendix 1. Design summaries 437Appendix 2. Sample design slide sets 457Appendix 3. Template worksheets and slides 489References 505Index 516. |
| Record Nr. | UNINA-9910817442103321 |
Meinert Curtis L
|
||
| Somerset, N.J., : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
| Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, c2009 |
| Descrizione fisica | 1 online resource (1247 p.) |
| Disciplina |
615.1
615.580724 615/.1 |
| Altri autori (Persone) | GadShayne C. <1948-> |
| Collana | Pharmaceutical Development Series |
| Soggetto topico |
Drugs - Testing
Clinical trials |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-36844-3
9786612368448 0-470-46636-7 0-470-46635-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology 10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards 16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index |
| Record Nr. | UNINA-9910455072803321 |
| Hoboken, NJ, : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
| Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, c2009 |
| Descrizione fisica | 1 online resource (1247 p.) |
| Disciplina |
615.1
615.580724 615/.1 |
| Altri autori (Persone) | GadShayne C. <1948-> |
| Collana | Pharmaceutical Development Series |
| Soggetto topico |
Drugs - Testing
Clinical trials |
| ISBN |
1-282-36844-3
9786612368448 0-470-46636-7 0-470-46635-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology 10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards 16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index |
| Record Nr. | UNINA-9910778685003321 |
| Hoboken, NJ, : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
| Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, c2009 |
| Descrizione fisica | 1 online resource (1247 p.) |
| Disciplina |
615.1
615.580724 615/.1 |
| Altri autori (Persone) | GadShayne C. <1948-> |
| Collana | Pharmaceutical Development Series |
| Soggetto topico |
Drugs - Testing
Clinical trials |
| ISBN |
1-282-36844-3
9786612368448 0-470-46636-7 0-470-46635-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology 10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards 16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index |
| Record Nr. | UNINA-9910816984703321 |
| Hoboken, NJ, : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in older people / / edited by Antonio Cherubini [and five others] ; contributors Heather Allore [and thirty five others]
| Clinical trials in older people / / edited by Antonio Cherubini [and five others] ; contributors Heather Allore [and thirty five others] |
| Pubbl/distr/stampa | Chichester, England : , : Wiley Blackwell, , 2015 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina | 610.72/40846 |
| Soggetto topico |
Clinical trials
Gerontology - Research |
| ISBN |
1-118-32348-3
1-118-32343-2 1-118-32347-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The exclusion of older subjects from clinical trials : the predict study / Antonio Cherubini, Peter Crome -- Clinical trials in older adults : a point of view from the industry / Susanna Del Signore, Philippe Guillet -- Ethical issues in clinical trials involving older subjects : the right to participate in clinical trials and have access to care; the protection of vulnerable subjects and the issue of informed consent / Emmanuel Hirsch, Paul-Loup Weil-Dubuc -- Mastering the design of clinical trials for older persons : the tension between external validity and feasibility / Luigi Ferrucci, Stephanie Studenski -- Pharmacokinetic and pharmacodynamic studies in older adults / Arduino A Mangoni, Paul AF Jansen, Stephen H.D. Jackson -- The role of comprehensive geriatric assessment of older adults in clinical studies / Graziano Onder, Agnese Collamati, Andrea Poscia, Roberto Bernabei -- Statistical issues in designing and interpreting clinical trials in older adults / Heather Allore, Mark A. Espeland, Michael E. Miller -- Challenges in implementing large-scale clinical trials in moderately functioning older adults / Stephen D. Anton, Sandrine Sourdet, Marco Pahor, & Todd Manini -- Clinical trials in Alzheimer's disease / Julien Delrieu , Bruno Vellas -- Clinical trials in late-life mood disorders / Lucio Ghio, Werner Natta, Marco Vaggi, Luigi Ferrannini -- Clinical trials for conditions of low muscle mass and strength / Stephanie Studenski, Rosaly Correa-de-Araujo and Luigi Ferrucci -- Clinical trials of cancer treatment in the elderly / Lodovico Balducci, Iordanis Gravanis, Francesco Pignatti -- Clinical trials in nursing homes : challenges and practical solutions / Sandra Simmons, Barbara Resnik, John Schnelle, Joe Ouslander. |
| Record Nr. | UNINA-9910137494203321 |
| Chichester, England : , : Wiley Blackwell, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in older people / / edited by Antonio Cherubini [and five others] ; contributors Heather Allore [and thirty five others]
| Clinical trials in older people / / edited by Antonio Cherubini [and five others] ; contributors Heather Allore [and thirty five others] |
| Pubbl/distr/stampa | Chichester, England : , : Wiley Blackwell, , 2015 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina | 610.72/40846 |
| Soggetto topico |
Clinical trials
Gerontology - Research |
| ISBN |
1-118-32348-3
1-118-32343-2 1-118-32347-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The exclusion of older subjects from clinical trials : the predict study / Antonio Cherubini, Peter Crome -- Clinical trials in older adults : a point of view from the industry / Susanna Del Signore, Philippe Guillet -- Ethical issues in clinical trials involving older subjects : the right to participate in clinical trials and have access to care; the protection of vulnerable subjects and the issue of informed consent / Emmanuel Hirsch, Paul-Loup Weil-Dubuc -- Mastering the design of clinical trials for older persons : the tension between external validity and feasibility / Luigi Ferrucci, Stephanie Studenski -- Pharmacokinetic and pharmacodynamic studies in older adults / Arduino A Mangoni, Paul AF Jansen, Stephen H.D. Jackson -- The role of comprehensive geriatric assessment of older adults in clinical studies / Graziano Onder, Agnese Collamati, Andrea Poscia, Roberto Bernabei -- Statistical issues in designing and interpreting clinical trials in older adults / Heather Allore, Mark A. Espeland, Michael E. Miller -- Challenges in implementing large-scale clinical trials in moderately functioning older adults / Stephen D. Anton, Sandrine Sourdet, Marco Pahor, & Todd Manini -- Clinical trials in Alzheimer's disease / Julien Delrieu , Bruno Vellas -- Clinical trials in late-life mood disorders / Lucio Ghio, Werner Natta, Marco Vaggi, Luigi Ferrannini -- Clinical trials for conditions of low muscle mass and strength / Stephanie Studenski, Rosaly Correa-de-Araujo and Luigi Ferrucci -- Clinical trials of cancer treatment in the elderly / Lodovico Balducci, Iordanis Gravanis, Francesco Pignatti -- Clinical trials in nursing homes : challenges and practical solutions / Sandra Simmons, Barbara Resnik, John Schnelle, Joe Ouslander. |
| Record Nr. | UNINA-9910813127403321 |
| Chichester, England : , : Wiley Blackwell, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in psychiatry [[e-book] /] / Brian S. Everitt, Simon Wessely
| Clinical trials in psychiatry [[e-book] /] / Brian S. Everitt, Simon Wessely |
| Autore | Everitt Brian |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 |
| Descrizione fisica | 1 online resource (vii, 236 pages) : illustrations |
| Disciplina | 616.89/10724 |
| Altri autori (Persone) |
EverittBrian S
WesselySimon |
| Soggetto topico |
Clinical trials
Mental illness Psychiatry - Research - Methodology |
| ISBN |
9786611309800
0-470-72385-8 1-281-30980-X 0-470-72384-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910796088903321 |
|
Everitt Brian
|
||
| Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in psychiatry [[e-book] /] / Brian S. Everitt, Simon Wessely
| Clinical trials in psychiatry [[e-book] /] / Brian S. Everitt, Simon Wessely |
| Autore | Everitt Brian |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 |
| Descrizione fisica | 1 online resource (vii, 236 pages) : illustrations |
| Disciplina | 616.89/10724 |
| Altri autori (Persone) |
EverittBrian S
WesselySimon |
| Soggetto topico |
Clinical trials
Mental illness Psychiatry - Research - Methodology |
| ISBN |
9786611309800
0-470-72385-8 1-281-30980-X 0-470-72384-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910819740603321 |
|
Everitt Brian
|
||
| Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler
| Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 |
| Descrizione fisica | 1 online resource (422 p.) |
| Disciplina | 615/.78 |
| Altri autori (Persone) |
HertzmanMarc
AdlerLawrence |
| Soggetto topico |
Psychopharmacology
Psychotropic drugs Clinical trials |
| ISBN |
1-282-54816-6
9786612548161 0-470-74918-0 0-470-74917-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials in Psychopharmacology; Contents; Acknowledgments; Introduction; List of Contributors; SECTION I: The Health Care Environment and Medications; 1. FDA Reform: D ́ej`a vu Encore; 1.1 Introduction; 1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus; 1.3 PDUFA shortens drug review times and eliminates the drug lag; 1.4 PDUFA timetables feed safety concerns; 1.5 FDA responds to safety concerns; 1.6 The pipeline problem; 1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative1.9 The impact of PDFUA on FDA; 1.10 Comparative medical benefits, comparative effectiveness and FDA; 1.11 FDA and non-inferiority trials; 1.12 FDA and CMS decisions on Medicare coverage; 1.13 Preemption: FDA's role in relation to liability litigation in state courts; 1.14 FDA's exclusivity in allowing access to experimental drugs; 1.15 Conclusions; 2. Do Antidepressants Cause Suicide?; 2.1 Some definitional problems 2.2 A brief history of the concerns of suicidality caused by antidepressants2.3 Politics rears its ugly head; 2.4 The FDA responds; 2.5 What changes in public policy wrought; 2.6 A funny thing happened on the way to the forum; 2.7 Meanwhile back at the ranch; 2.8 Moral (maybe); 3. The Genome, Genes and Brain - Tailored Drugs; 3.1 Introduction; 3.2 Issues in new drug development; 3.3 Early development of psychiatric pharmaceutical entities; 3.4 Advances in research technology; 3.5 Review of genetics; 3.6 Activation of genes by signal transduction cascades; 3.7 The human genome 3.8 The sequencing of the genome3.9 DNA variation; 3.10 Genes and illness; 3.11 Genomic findings, potential targets and new drug development; 3.12 Conclusion; 4. Patenting and Licensing Concerns in Psychiatric Genetics; 4.1 Genetic diagnoses in psychiatry; 4.2 The evolving patent landscape in psychiatry; 4.3 Approaches to solving potential problems; 4.4 Conclusions; 5. Women's Issues in Clinical Trials; 5.1 History; 5.2 Perceived advantages of excluding women; 5.3 Change in perspective; 5.4 Have things changed?; 5.5 Progress since 1993; 5.6 Reported current difficulties in including women 5.7 Contraception in clinical trials5.8 Drugs in lactating women; 5.9 How often do women take drugs during pregnancy?; 5.10 Ethical issues: risk/benefit analysis; 5.11 Adequate information; 5.12 Adolescent women; 5.13 Recruitment and retention of women; SECTION II: Clinical Trials and Mood Disorders; 6. Issues and Clues in the Pharmacological Treatment of Mood Disorders; 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment?; 6.2 Are there clues for the pharmacological treatment of mood disorders?; 6.3 Perspectives; 7. Bipolar Disorder 7.1 Introduction |
| Record Nr. | UNINA-9910139427703321 |
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler
| Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 |
| Descrizione fisica | 1 online resource (422 p.) |
| Disciplina | 615/.78 |
| Altri autori (Persone) |
HertzmanMarc
AdlerLawrence |
| Soggetto topico |
Psychopharmacology
Psychotropic drugs Clinical trials |
| ISBN |
1-282-54816-6
9786612548161 0-470-74918-0 0-470-74917-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials in Psychopharmacology; Contents; Acknowledgments; Introduction; List of Contributors; SECTION I: The Health Care Environment and Medications; 1. FDA Reform: D ́ej`a vu Encore; 1.1 Introduction; 1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus; 1.3 PDUFA shortens drug review times and eliminates the drug lag; 1.4 PDUFA timetables feed safety concerns; 1.5 FDA responds to safety concerns; 1.6 The pipeline problem; 1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative1.9 The impact of PDFUA on FDA; 1.10 Comparative medical benefits, comparative effectiveness and FDA; 1.11 FDA and non-inferiority trials; 1.12 FDA and CMS decisions on Medicare coverage; 1.13 Preemption: FDA's role in relation to liability litigation in state courts; 1.14 FDA's exclusivity in allowing access to experimental drugs; 1.15 Conclusions; 2. Do Antidepressants Cause Suicide?; 2.1 Some definitional problems 2.2 A brief history of the concerns of suicidality caused by antidepressants2.3 Politics rears its ugly head; 2.4 The FDA responds; 2.5 What changes in public policy wrought; 2.6 A funny thing happened on the way to the forum; 2.7 Meanwhile back at the ranch; 2.8 Moral (maybe); 3. The Genome, Genes and Brain - Tailored Drugs; 3.1 Introduction; 3.2 Issues in new drug development; 3.3 Early development of psychiatric pharmaceutical entities; 3.4 Advances in research technology; 3.5 Review of genetics; 3.6 Activation of genes by signal transduction cascades; 3.7 The human genome 3.8 The sequencing of the genome3.9 DNA variation; 3.10 Genes and illness; 3.11 Genomic findings, potential targets and new drug development; 3.12 Conclusion; 4. Patenting and Licensing Concerns in Psychiatric Genetics; 4.1 Genetic diagnoses in psychiatry; 4.2 The evolving patent landscape in psychiatry; 4.3 Approaches to solving potential problems; 4.4 Conclusions; 5. Women's Issues in Clinical Trials; 5.1 History; 5.2 Perceived advantages of excluding women; 5.3 Change in perspective; 5.4 Have things changed?; 5.5 Progress since 1993; 5.6 Reported current difficulties in including women 5.7 Contraception in clinical trials5.8 Drugs in lactating women; 5.9 How often do women take drugs during pregnancy?; 5.10 Ethical issues: risk/benefit analysis; 5.11 Adequate information; 5.12 Adolescent women; 5.13 Recruitment and retention of women; SECTION II: Clinical Trials and Mood Disorders; 6. Issues and Clues in the Pharmacological Treatment of Mood Disorders; 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment?; 6.2 Are there clues for the pharmacological treatment of mood disorders?; 6.3 Perspectives; 7. Bipolar Disorder 7.1 Introduction |
| Record Nr. | UNINA-9910813016803321 |
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Clinical trials
(243)
- Clinical Trials as Topic (26)
- Drugs - Testing (25)
- Medicine - Research (11)
- Clinical medicine - Research (9)